证券代码：603987 证券简称：康德莱 公告编号：2025-014 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 上海康德莱企业发展集团股份有限公司 关于参加 2025 年上海辖区上市公司年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 总经理：张维鑫 董事会秘书：顾佳俊 财务总监：沈晓如 独立董事：邵军 投资者可于 2025 年 05 月 08 日（星期四）至 05 月 14 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dm@kdlchina.net 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海康德莱企业发展集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 19 日发布公司 2024 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603987 证券简称：康德莱 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 □适用 √不适用 ...

Financial Data and Indicators - The basic earnings per share (EPS) for Q1 2025 remained unchanged at 0.1400 CNY compared to Q1 2024, but decreased from 0.1900 CNY in Q1 2023 [1] - The net asset per share increased by 5.87% to 5.95 CNY from 5.62 CNY in Q1 2024, and from 5.26 CNY in Q1 2023 [1] - The retained earnings per share rose by 10.71% to 3.41 CNY compared to 3.08 CNY in Q1 2024, and increased from 2.86 CNY in Q1 2023 [1] - The operating revenue decreased by 3.86% to 5.48 billion CNY from 5.7 billion CNY in Q1 2024, and significantly decreased from 6.87 billion CNY in Q1 2023 [1] - The net profit remained stable at 0.61 billion CNY compared to Q1 2024, but decreased from 0.85 billion CNY in Q1 2023 [1] - The return on equity (ROE) decreased by 5.22% to 2.36% from 2.49% in Q1 2024, and decreased from 3.75% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 20,244.86 million shares, accounting for 46.35% of the circulating shares, with a decrease of 203.63 million shares compared to the previous period [1] - Shanghai Kangdelai Holding Group Co., Ltd. remains the largest shareholder with 17,286.82 million shares, representing 39.58% of the total share capital, unchanged from the previous period [2] - New entrants to the top ten shareholders include China Bank's investment fund with 578.47 million shares (1.32%) and China Construction Bank's investment fund with 421.00 million shares (0.96%) [2] - Notable exits from the top ten shareholders include the招商量化精选股票A fund, which exited with 531.47 million shares (1.21%) [2] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [3]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 548,144,759.22, a decrease of 3.82% compared to CNY 569,931,434.38 in the same period last year[4]. - Net profit attributable to shareholders was CNY 60,704,201.61, reflecting a slight increase of 0.28% from CNY 60,535,925.93 year-on-year[4]. - Total revenue for Q1 2025 was RMB 548.14 million, a decrease of 3.1% compared to RMB 569.93 million in Q1 2024[15]. - Net profit for Q1 2025 was RMB 64.42 million, a decrease of 3.5% from RMB 66.75 million in Q1 2024[16]. - The company reported a total profit of RMB 71.51 million for Q1 2025, compared to RMB 73.01 million in Q1 2024, reflecting a decline of 2.1%[16]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to -CNY 13,283,794.48, compared to -CNY 44,696,620.75 in the previous year, indicating a positive trend[4]. - The net cash flow from operating activities for Q1 2025 was negative RMB 13.28 million, an improvement from negative RMB 44.70 million in Q1 2024[19]. - Cash and cash equivalents at the end of Q1 2025 were RMB 304.73 million, down from RMB 336.42 million at the end of Q1 2024[20]. - The cash and cash equivalents decreased to RMB 333,261,416.30 from RMB 368,125,548.49, a decline of approximately 9.5%[11]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,171,843,144.22, up 0.57% from CNY 4,148,354,602.76 at the end of the previous year[5]. - The total liabilities of the company were RMB 1,197,320,591.04, down from RMB 1,238,606,553.10, representing a reduction of approximately 3.3%[13]. - The company's current assets totaled RMB 1,842,247,931.06, slightly up from RMB 1,837,073,921.83 in the previous period[12]. - The company's total non-current assets amounted to RMB 2,329,595,213.16, up from RMB 2,311,280,680.93, indicating a growth of approximately 0.8%[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,817[8]. - The largest shareholder, Shanghai Kangdai Holding Group Co., Ltd., holds 39.5% of the shares, totaling 172,868,225 shares[8]. - Shareholders' equity attributable to the parent company increased by 2.40% to CNY 2,600,690,954.04 from CNY 2,539,635,805.75[5]. - The company's equity attributable to shareholders increased to RMB 2,600,690,954.04 from RMB 2,539,635,805.75, marking an increase of about 2.4%[13]. Operational Efficiency - Total operating costs for Q1 2025 were RMB 482.30 million, down 4.6% from RMB 505.50 million in Q1 2024[15]. - Research and development expenses for Q1 2025 were RMB 18.89 million, a decrease of 10.3% from RMB 21.05 million in Q1 2024[15]. - The company experienced a decrease in sales revenue from services, with cash received from sales at RMB 523.21 million, down from RMB 535.99 million in Q1 2024[19]. Earnings Per Share - The basic and diluted earnings per share remained stable at CNY 0.14, unchanged from the previous year[4]. - Basic and diluted earnings per share remained unchanged at RMB 0.14 for both Q1 2025 and Q1 2024[16]. Government Support - The company received government subsidies amounting to CNY 1,003,193.29, which positively impacted the financial results[6].

康德莱（603987）公告，2025年第一季度营收为5.48亿元，同比下降3.82%；净利润为6070.42万元，同 比增长0.28%。 ...

Market Overview - The Shanghai Composite Index closed at 3299.76 points, above the annual line, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,121.207 billion yuan [1] Stocks Breaking Annual Line - A total of 106 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Youbuxun: 17.49% deviation, closing price at 15.18 yuan, with a daily increase of 20.00% and turnover rate of 6.57% [1] - Fujilai: 14.53% deviation, closing price at 29.09 yuan, with a daily increase of 20.01% and turnover rate of 30.40% [1] - Chongqing Construction: 8.33% deviation, closing price at 3.01 yuan, with a daily increase of 9.85% and turnover rate of 2.93% [1] Additional Stocks with Minor Deviations - Jiangxi Copper, Meirya, and Laimu Co. have just crossed the annual line with smaller deviation rates [1] - Other stocks with notable performance include: - Changjiang Investment: 7.98% deviation, closing price at 8.01 yuan, with a daily increase of 10.03% [1] - Qingtang City: 7.70% deviation, closing price at 3.78 yuan, with a daily increase of 9.88% [1] - Shenchuan A: 7.45% deviation, closing price at 6.75 yuan, with a daily increase of 9.93% [1] Summary of Stocks with Deviation Rates - A detailed table lists various stocks, their daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates, highlighting the performance of stocks like: - Dongjiang Environmental: 3.70% deviation, closing price at 4.28 yuan, with a daily increase of 10.03% [1] - Feinan Resources: 3.56% deviation, closing price at 19.88 yuan, with a daily increase of 3.92% [1] - The table provides a comprehensive view of the market dynamics and stock performances on the day [2]

Core Viewpoint - The article discusses the financial performance and market position of Kangdai, highlighting a decline in revenue and profit while emphasizing the company's efforts in product innovation and market adaptation [3][4][5]. Financial and Market Performance - In 2024, Kangdai reported total revenue of 2.261 billion yuan, a year-on-year decrease of 7.79% due to changes in the market environment affecting product sales [3][5]. - The net profit attributable to shareholders was 215 million yuan, down 6.75% year-on-year, although the fourth quarter saw a net profit of 50.29 million yuan, an increase of 13.73% compared to the previous year [5]. - The company's total expenses for sales, management, and finance amounted to 384 million yuan, accounting for 16.96% of revenue, a slight decrease of 0.17% year-on-year [5]. - The net cash flow from operating activities was 292 million yuan, down 33.47% year-on-year [5]. - Kangdai's asset-liability ratio was 29.86% in 2024, a decrease of 12.49% from 2023, indicating improved debt repayment capability [5]. Main Business and Business Model - Kangdai's primary business includes the research, production, sales, and service of medical devices such as medical puncture needles and infusion devices [3]. - The business model primarily focuses on self-branded product sales while also providing related medical device services [3]. Comprehensive Analysis - The overall market size of the medical device industry continues to grow, but competition is intensifying, particularly due to the normalization of centralized procurement [4]. - Despite revenue and profit declines, Kangdai has seen slight growth in its proprietary product business and is actively enhancing product quality and driving technological innovation [4]. About Kangdai - Established in 1987 and headquartered in Shanghai, Kangdai specializes in the research, production, and sales of disposable medical puncture devices [5]. - The company has been recognized as a "High-tech Enterprise" and has received support for its innovative projects, including the development of high-tech medical products [7]. Products and Technology - Kangdai's product line includes medical puncture needles, infusion devices, high polymer consumables, interventional consumables, and medical packaging, among others [7]. - The company employs advanced technology and equipment to ensure the highest quality of medical devices [7]. Market and Cooperation - Kangdai is adapting to changes in medical insurance policies and centralized procurement by employing a marketing model that combines agency distribution, delivery, and service [8]. - The company's products are sold domestically and exported to over 50 countries and regions, establishing long-term cooperative relationships [8].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月21日， 康德莱 发布了2024年年报。 # 财务与市场表现 # 主营业务与商业模式 康德莱的主要业务包括 医用穿刺针、医用输注器械等医疗器械的研发、生产、销售和服务 。其商业模式主要 以自有品牌产品销售为主，同时提供相关的医疗器械服务。2024年，公司营业收入为22.61亿元，同比下降 7.79%。这一下降主要源于市场环境的变化，导致公司产品销售受到一定影响。 # 综合分析 医疗器械行业整体市场规模持续增长，但市场竞争也日益激烈。尤其是在医疗器械集中带量采购常态化的背景 下，康德莱的市场份额和盈利能力受到一定挤压。尽管如此，康德莱通过调整经营策略、优化成本结构和推进 新产品上市等措施，试图稳住基本盘。 康德莱的核心驱动力在于其持续的研发投入和产品创新。 2024年，公司扣非净利润为2.11亿元，同比下降 5.44%。尽管面临营收和利润的下滑，但公司在自有产品业务上仍略有增长。此外，公司在医疗器械行业标 准制修订加速的背景下，积极提升产品质量，推动技术创新。 # 关于康德莱 营 ...

2024 年年度股东会 上海康德莱企业发展集团股份有限公司 会议资料 二零二五年四月 上海康德莱企业发展集团股份有限公司 2024 年年度股东会会议资料目录 8、审议《关于确认公司 2024 年度日常性关联交易及预计公司 2025 年度日常性 关联交易的议案》 9、审议《关于确认公司 2025 年度非独立董事、监事及高级管理人员薪酬方案的 议案》 10、审议《关于续聘立信会计师事务所（特殊普通合伙）为公司 2025 年度财务 及内部控制审计机构的议案》 一、会议议程 二、会议须知 三、股东会审议议案 1、审议《2024 年度董事会工作报告》 2、审议《2024 年度监事会工作报告》 3、审议《2024 年度独立董事述职报告（邵军）》 4、审议《2024 年度独立董事述职报告（郭超）》 5、审议《2024 年度独立董事述职报告（杨峰）》 6、审议《关于公司 2024 年度利润分配预案的议案》 7、审议《公司 2024 年度报告及其摘要》 上海康德莱企业发展集团股份有限公司 2024 年年度股东会会议议程 会议时间：2025 年 5 月 12 日（周一） 上午 09:30 会议程序： | 序号 | 会议议案 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东会召开日期：2025年5月12日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系统 证券代码：603987 证券简称：康德莱 公告编号：2025-013 一、 召开会议的基本情况 上海康德莱企业发展集团股份有限公司 关于召开 2024 年年度股东会的通知 (一) 股东会类型和届次 2024 年年度股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 12 日 9 点 30 分 召开地点：上海市嘉定区高潮路 658 号会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 12 日 至 2025 年 5 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9 ...